

Glicturn 30 MR Tablet

Brand Name: Glicturn 30 MR Tablet

Dosage Form: Modified Release (MR) Tablet

Composition:

Each modified release tablet contains:

- Gliclazide IP 30 mg (Modified Release)

Description:

Glicturn 30 MR Tablet contains Gliclazide, a second-generation sulfonylurea oral antidiabetic agent formulated as a modified release tablet. It is indicated for the management of type 2 diabetes mellitus in adults whose blood glucose levels are not adequately controlled with diet, exercise, and lifestyle modification alone. The modified release formulation provides sustained release of Gliclazide, ensuring effective 24-hour glycemic control with once-daily dosing.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus in adults
- Patients inadequately controlled with diet and exercise alone
- Adjunct to lifestyle modification for improved glycemic control
- Combination therapy with other oral antidiabetic agents or insulin when appropriate

It helps lower fasting and postprandial blood glucose levels and supports long-term glycemic control.

Dosage & Administration:

Dosage should be individualized and administered as directed by the physician.

The tablet should be taken once daily, preferably with breakfast.

Swallow the modified release tablet whole with water. Do not crush, chew, or break the tablet.

Regular monitoring of blood glucose and HbA1c is recommended during treatment.

Pharmacological Action:

- Gliclazide is a second-generation sulfonylurea that stimulates insulin secretion from functional pancreatic β -cells by blocking ATP-sensitive potassium channels.
- This leads to membrane depolarization, calcium influx, and enhanced insulin release.
- The modified release formulation maintains sustained plasma drug concentrations, providing prolonged glycemic control while minimizing fluctuations in blood glucose levels.

Side Effects:

Common side effects include hypoglycemia, headache, dizziness, nausea, abdominal discomfort, constipation, diarrhea, and weight gain.

Less commonly, skin rash, pruritus, elevated liver enzymes, or gastrointestinal disturbances may occur. Rarely, hematological disorders or severe hypersensitivity reactions have been reported.

Precautions & Warnings:

- Monitor blood glucose and HbA1c regularly during treatment.
- Educate patients regarding the recognition and management of hypoglycemia.
- Use with caution in patients with hepatic or renal impairment.
- Skipping meals, excessive exercise, or alcohol consumption may increase the risk of hypoglycemia.

- Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.
- Use during pregnancy and lactation only if considered essential by the physician.

Drug Interactions:

May interact with insulin, other oral antidiabetic agents, beta-blockers, ACE inhibitors, NSAIDs, fluconazole, corticosteroids, thiazide diuretics, rifampicin, and alcohol. Close monitoring of blood glucose is recommended during concomitant therapy, and dosage adjustments may be required.

Storage:

Store below 25°C in a cool, dry place.

Protect from light and moisture.

Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I, Panchkula-134113

Corporate Office :

Plot no. 307, Industrial Area Phase-2,

Panchkula, Haryana -134113

TM: Trademark Applied for